Psychoactive medication use and neurocognitive function in adult survivors of childhood cancer: A report from the childhood cancer survivor study

Pediatric Blood and Cancer

Volumn 60, Issue 3, 2013, Pages 486-493

  Brinkman, Tara M ^a   Zhang, Nan ^a   Ullrich, Nicole J ^b   Brouwers, Pim ^c   Green, Daniel M ^a   Srivastava, Deo Kumar ^a   Zeltzer, Lonnie K ^d   Stovall, Marilyn ^e   Robison, Leslie L ^a   Krull, Kevin R ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Neurocognition; Psychoactive medication; Survivorship

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BRAIN RADIATION; CANCER SURVIVOR; CEREBROVASCULAR ACCIDENT; CHILDHOOD CANCER; COGNITION; COGNITIVE DEFECT; DISTRESS SYNDROME; EMOTIONALITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; PAIN; PRESCRIPTION; PRIORITY JOURNAL; SEIZURE; SELF REPORT;

ADOLESCENT; ADULT; AGE OF ONSET; CHILD; CHILD, PRESCHOOL; COGNITION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEOPLASMS; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTROPIC DRUGS; QUESTIONNAIRES; RESEARCH REPORT; SURVIVORS; YOUNG ADULT;

EID: 84872470599     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24255     Document Type: Article

References (50)

1. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572-1582.
2. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. JAMA 2003; 290: 1583-1592.
3. Brinkman TM, Ullrich NJ, Zhang N, et al. Prevalence and predictors of prescription psychoactive medication use in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Manuscript submitted.
4. Ellenberg L, Liu Q, Gioia G, et al. Neurocognitive status in long-term survivors of childhood CNS malignancies: A report from the Childhood Cancer Survivor Study. Neuropsychology 2009; 23: 705-717.
5. Mulhern RK, Palmer SL. Neurocognitive late effects in pediatric cancer. Curr Probl Cancer 2003; 27: 177-197.
6. Maddrey AM, Bergeron JA, Lombardo ER, et al. Neuropsychological performance and quality of life of 10 year survivors of childhood medulloblastoma. J Neuroonco 2005; 72: 245-253.
7. Spiegler BJ, Bouffet E, Greenberg ML, et al. Change in neurocognitive functioning after treatment with cranial radiation in childhood. J Clin Oncol 2004; 22: 706-713.
8. Waber DP, Carpentieri SC, Klar N, et al. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol 2000; 22: 206-213.
9. Kadan-Lottick NS, Brouwers P, Breiger D, et al. A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood 2009; 114: 1746-1752.
10. Mrakotsky CM, Silverman LB, Dahlberg SE, et al. Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: Report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Pediatr Blood Cancer 2011; 57: 492-498.
11. Reeves CB, Palmer SL, Reddick WE, et al. Attention and memory functioning among pediatric patients with medulloblastoma. J Pediatr Psychol 2006; 31: 272-280.
12. Reddick WE, White HA, Glass JO, et al. Developmental model relating white matter volume to neurocognitive deficits in pediatric brain tumor survivors. Cancer 2003; 97: 2512-2519.
13. Mabbott DJ, Penkman L, Witol A, et al. Core neurocognitive functions in children treated for posterior fossa tumors. Neuropsychology 2008; 22: 159-168.
14. Krull KR, Annett RD, Pan Z, et al. Neurocognitive functioning and health-related behaviours in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Eur J Cancer 2011; 47: 1380-1388.
15. Ness KK, Gurney JG, Zeltzer LK, et al. The impact of limitations in physical, executive, and emotional function on health-related quality of life among adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Arch Phys Med Rehabil 2008; 89: 128-136.
16. van Laar MW, Volkerts ER, Verbaten MN, et al. Differential effects of amitriptyline, nefazodone and paroxetine on performance and brain indices of visual selective attention and working memory. Psychopharmacology (Berlin) 2002; 162: 351-363.
17. Amado-Boccara I, Gougoulis N, Poirier Littre MF, et al. Effects of antidepressants on cognitive functions: A review. Neurosci Biobehav Rev 1995; 19: 479-493.
18. Schmitt JA, Ramaekers JG, Kruizinga MJ, et al. Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J Psychopharmacol 2002; 16: 207-214.
19. Schmitt JA, Kruizinga MJ, Riedel WJ. Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol 2001; 15: 173-179.
20. Meador KJ, Loring DW, Hulihan JF, et al. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 2003; 60: 1483-1488.
21. Loring DW, Williamson DJ, Meador KJ, et al. Topiramate dose effects on cognition: A randomized double-blind study. Neurology 2011; 76: 131-137.
22. Gualtieri CT, Johnson LG, Benedict KB. Neurocognition in depression: Patients on and off medication versus healthy comparison subjects. J Neuropsychiatry Clin Neurosci 2006; 18: 217-225.
23. Leisenring WM, Mertens AC, Armstrong GT, et al. Pediatric cancer survivorship research: Experience of the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2319-2327.
24. Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: A multi-institutional collaborative project. Med Pediatr Oncol 2002; 38: 229-239.
25. Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: A National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 2009; 27: 2308-2318.
26. Krull KR, Gioia G, Ness KK, et al. Reliability and validity of the childhood cancer survivor study neurocognitive questionnaire. Cancer 2008; 113: 2188-2197.
27. American Society of Health-System Pharmacists. AHFS Drug Information. Available from: http://www.ahfsdruginformation.com/. Accessed June 10, 2011.
28. Derogatis L. Brief Symptom Inventory (BSI): Administration, scoring, and procedures manual. Minneapolis, MN: NCS Pearson; 2000.
29. Kadan-Lottick NS, Zeltzer LK, Liu Q, et al. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst 2010; 102: 881-893.
30. Meador KJ, Loring DW, Vahle VJ, et al. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 2005; 64: 2108-2114.
31. Ramaekers JG, Muntjewerff ND, O'Hanlon JF. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol 1995; 39: 397-404.
32. O'Hanlon JF, Robbe HW, Vermeeren A, et al. Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. J Clin Psychopharmacol 1998; 18: 212-221.
33. Riedel WJ, Eikmans K, Heldens A, et al. Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment. J Psychopharmacol 2005; 19: 12-20.
34. Cohen R, Lohr I, Paul R, et al. Impairments of attention and effort among patients with major affective disorders. J Neuropsychiatry Clin Neurosci 2001; 13: 385-395.
35. Farrin L, Hull L, Unwin C, et al. Effects of depressed mood on objective and subjective measures of attention. J Neuropsychiatry Clin Neurosci 2003; 15: 98-104.
36. Mulhern RK, Merchant TE, Gajjar A, et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004; 5: 399-408.
37. Elger CE, Helmstaedter C, Kurthen M. Chronic epilepsy and cognition. Lancet Neurol 2004; 3: 663-672.
38. Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003; 26: 25-40.
39. Martinez-Aran A, Vieta E, Colom F, et al. Cognitive impairment in euthymic bipolar patients: Implications for clinical and functional outcome. Bipolar Disord 2004; 6: 224-232.
40. Hill SK, Bishop JR, Palumbo D, et al. Effect of second-generation antipsychotics on cognition: Current issues and future challenges. Expert Rev Neurother 2010; 10: 43-57.
41. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: Fourth edition, text revision. Washington, DC: American Psychiatric Association; 2000.
42. Breitbart W, Alici-Evcimen Y. Update on psychotropic medications for cancer-related fatigue. J Natl Compr Canc Netw 2007; 5: 1081-1091.
43. Majer M, Welberg LA, Capuron L, et al. Neuropsychological performance in persons with chronic fatigue syndrome: Results from a population-based study. Psychosom Med 2008; 70: 829-836.
44. Clanton NR, Klosky JL, Li C, et al. Fatigue, vitality, sleep, and neurocognitive functioning in adult survivors of childhood Cancer: A report from the childhood cancer survivor study. Cancer 2011; 117: 2559-2568.
45. Blockmans D, Persoons P, Van Houdenhove B, et al. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? Am J Med 2006; 119: 167e123-130.
46. Advokat C. What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neurosci Biobehav Rev 2010; 34: 1256-1266.
47. Turner DC, Robbins TW, Clark L, et al. Relative lack of cognitive effects of methylphenidate in elderly male volunteers. Psychopharmacology (Berl) 2003; 168: 455-464.
48. Keefe FJ, Lumley M, Anderson T, et al. Pain and emotion: New research directions. J Clin Psychol 2001; 57: 587-607.
49. van Middendorp H, Lumley MA, Jacobs JW, et al. The effects of anger and sadness on clinical pain reports and experimentally-induced pain thresholds in women with and without fibromyalgia. Arthritis Care Res (Hoboken) 2010; 62: 1370-1376.
50. Calley CS, Tillman GD, Womack K, et al. Subjective report of word-finding and memory deficits in normal aging and dementia. Cogn Behav Neurol 2010; 23: 185-191.